389 related articles for article (PubMed ID: 36062811)
1. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion.
Bachelez H; Barker J; Burden AD; Navarini AA; Krueger JG
Expert Rev Clin Immunol; 2022 Oct; 18(10):1033-1047. PubMed ID: 36062811
[TBL] [Abstract][Full Text] [Related]
2. A brief guide to pustular psoriasis for primary care providers.
Crowley JJ; Pariser DM; Yamauchi PS
Postgrad Med; 2021 Apr; 133(3):330-344. PubMed ID: 33118424
[TBL] [Abstract][Full Text] [Related]
3. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
4. Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis.
Lan Y; Wu X; Zhong X; Song P; Liu L; Liu Y; Ai X; Han C; Zhang Z
Exp Dermatol; 2024 Feb; 33(2):e15026. PubMed ID: 38414093
[TBL] [Abstract][Full Text] [Related]
5. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.
Burden AD
Expert Rev Clin Immunol; 2023 May; 19(5):473-481. PubMed ID: 36960829
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris.
Li X; Chen M; Fu X; Zhang Q; Wang Z; Yu G; Yu Y; Qin P; Wu W; Pan F; Liu H; Zhang F
J Dermatol Sci; 2014 Nov; 76(2):132-8. PubMed ID: 25212972
[TBL] [Abstract][Full Text] [Related]
7. Different Clinical Features of Pediatric Generalized Pustular Psoriasis in Patients with or without IL36RN Variants.
Wang Z; Xiang X; Chen Y; Qi Z; Miao C; Liu Y; Zhao X; Zhang Y; Zhang Z; Li W; Xu Z; Ma L
Dermatology; 2023; 239(2):217-226. PubMed ID: 36577391
[TBL] [Abstract][Full Text] [Related]
8. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants.
Sugiura K
J Dermatol Sci; 2014 Jun; 74(3):187-92. PubMed ID: 24656634
[TBL] [Abstract][Full Text] [Related]
9. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist.
Sugiura K; Takemoto A; Yamaguchi M; Takahashi H; Shoda Y; Mitsuma T; Tsuda K; Nishida E; Togawa Y; Nakajima K; Sakakibara A; Kawachi S; Shimizu M; Ito Y; Takeichi T; Kono M; Ogawa Y; Muro Y; Ishida-Yamamoto A; Sano S; Matsue H; Morita A; Mizutani H; Iizuka H; Muto M; Akiyama M
J Invest Dermatol; 2013 Nov; 133(11):2514-2521. PubMed ID: 23698098
[TBL] [Abstract][Full Text] [Related]
10. Generalized pustular psoriasis: practical recommendations for Spanish primary care and emergency physicians.
Rivera-Diaz R; Epelde F; Heras-Hitos JA; Martínez Virto AM; Dávalos Marin AJ; Senán Sanz MR; Carrascosa JM
Postgrad Med; 2023 Nov; 135(8):766-774. PubMed ID: 38019177
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of Generalized Pustular Psoriasis.
Marrakchi S; Puig L
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):13-19. PubMed ID: 35061228
[TBL] [Abstract][Full Text] [Related]
13. Generalized pustular psoriasis: current management status and unmet medical needs in Japan.
Komine M; Morita A
Expert Rev Clin Immunol; 2021 Sep; 17(9):1015-1027. PubMed ID: 34402355
[TBL] [Abstract][Full Text] [Related]
14. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.
Johnston A; Xing X; Wolterink L; Barnes DH; Yin Z; Reingold L; Kahlenberg JM; Harms PW; Gudjonsson JE
J Allergy Clin Immunol; 2017 Jul; 140(1):109-120. PubMed ID: 28043870
[TBL] [Abstract][Full Text] [Related]
15. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis.
Krueger J; Puig L; Thaçi D
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):51-64. PubMed ID: 35061230
[TBL] [Abstract][Full Text] [Related]
16. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab.
Hawkes JE; Visvanathan S; Krueger JG
Front Immunol; 2023; 14():1292941. PubMed ID: 38077370
[TBL] [Abstract][Full Text] [Related]
17. Expression of interleukin-36 receptor antagonist in a patient with generalized pustular psoriasis harboring the p.Pro82Leu variant in the IL36RN gene.
Mizukawa I; Kamata M; Shimizu T; Ito M; Watanabe A; Uchida H; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Sugiura K; Tada Y
J Dermatol; 2023 Dec; 50(12):1608-1613. PubMed ID: 37525499
[TBL] [Abstract][Full Text] [Related]
18. [Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab].
Müller VL; Kreuter A
Dermatologie (Heidelb); 2023 May; 74(5):356-359. PubMed ID: 36943426
[TBL] [Abstract][Full Text] [Related]
19. A review of disease burden and clinical management for generalized pustular psoriasis in China.
Lu J; Shi Y
Expert Rev Clin Immunol; 2022 Oct; 18(10):1023-1032. PubMed ID: 36040447
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation.
Komatsuda S; Kamata M; Chijiwa C; Namiki K; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Abe K; Yamamoto T; Aozasa N; Sugiura K; Tada Y
J Dermatol; 2019 Jan; 46(1):73-75. PubMed ID: 30474867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
